S. 832 — 119th Congress
Federal bill
EPIC Act of 2025
- Title
- EPIC Act of 2025
- Official title
- A bill to amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
- Type
- Senate bill
- Congress
- 119th Congress
- Chamber of origin
- Senate
- Introduced
- 2025-03-04
- Latest action
- Read twice and referred to the Committee on Finance.
- Latest action date
- 2025-03-04
Organizations that named this bill in federal lobbying filings
- GSK (FKA GLAXOSMITHKLINE INC.) Federal lobbying client (LDA)
- PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA Federal lobbying client (LDA)
- BOEHRINGER INGELHEIM USA CORPORATION Federal lobbying client (LDA)
- AARP Federal lobbying client (LDA)
- BAYER CORPORATION (CONSOLIDATED REPORT) Federal lobbying client (LDA)
- PUBLIC CITIZEN Federal lobbying client (LDA)
- THE ALS ASSOCIATION Federal lobbying client (LDA)
Federal lobbying filings naming this bill
U.S. Senate Lobbying Disclosure Act database. A filing names bills, issues and agencies — never the member lobbied — so these rows point only at the client organization, and none of them says any member of Congress was lobbied about this bill. The count is filings in this site's LDA slice, not the
- GSK (FKA GLAXOSMITHKLINE INC.) cited in the filing's issue text 6 filings
- PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA cited in the filing's issue text 6 filings
- BOEHRINGER INGELHEIM USA CORPORATION cited in the filing's issue text 5 filings
- AARP cited in the filing's issue text 3 filings
- BAYER CORPORATION (CONSOLIDATED REPORT) cited in the filing's issue text 3 filings
- PUBLIC CITIZEN cited in the filing's issue text 2 filings
- THE ALS ASSOCIATION cited in the filing's issue text 1 filing